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Lipid mediators can trigger physiological responses by activating nuclear hormone receptors, such as the peroxisome proliferator-
activated receptors (PPARs). PPARs, in turn, control the expression of networks of genes encoding proteins involved in all aspects
of lipid metabolism. In addition, PPARs are tumor growth modifiers, via the regulation of cancer cell apoptosis, proliferation, and
diﬀerentiation, and through their action on the tumor cell environment, namely, angiogenesis, inflammation, and immune cell
functions. Epidemiological studies have established that tumor progression may be exacerbated by chronic inflammation. Here,
we describe the production of the lipids that act as activators of PPARs, and we review the roles of these receptors in inflammation
and cancer. Finally, we consider emerging strategies for therapeutic intervention.
Copyright © 2008 L. Michalik and W. Wahli. This is an open access article distributed under the Creative Commons Attribution
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1. INTRODUCTION
Signal lipids are known to trigger systemic physiologi-
cal responses, to control inflammatory reactions, and to
regulate key cellular processes, such as cellular energy
metabolism, cell survival, proliferation, migration, and dif-
ferentiation [1]. Among these lipids, fatty acids, diverse
fatty acid derivatives, some eicosanoids, and sterol deriva-
tives are modulators of gene expression via binding and
activation of the nuclear hormone receptors (NHRs)
peroxisome proliferator-activated receptors (PPARs), liver
X receptors (LXRs), and farnesoid X receptor (FXR)
[2]. These transcription factors control genes that regu-
late lipid homeostasis [2] and, for PPARs in particular,
inflammatory responses [3]. Disturbance of lipid signal-
ing and/or NHR pathways promotes the progression of
a long list of imbalances and diseases, such as obe-
sity, type 2 diabetes, chronic inflammation, cardiovascu-
lar diseases, cancer, hypertension, degenerative diseases,
autoimmune diseases, and a few others [1, 2]. Important
cross-regulation exists between lipid signaling and NHR
pathways, which generates a variety of responses depen-
dent on signaling networks that are often tissue-specific
[1].
In this paper, we propose an integrated view of the
production of the lipids that activate PPARs, and of the
functions of these receptors in inflammation and cancer. We
conclude with comments on therapeutic opportunities.
The three PPAR isotypes (PPARα or NR1C1, PPARβ/δ
or NR1C2, and PPARγ or NR1C3) share a high degree
of structural similarity with all members of the nuclear
hormone receptor superfamily [4–6]. The cellular and
systemic roles that have been attributed to PPARs extend
far beyond the control of hepatic peroxisome prolifera-
tion in the rodents after which they were initially named
[2, 3, 7]. PPARs exhibit isotype-specific tissue expression
patterns, with PPARα expressed at high levels in organs
with a significant catabolism of fatty acids, PPARβ/δ in
all cell types analyzed so far with levels depending on the
extent of cell proliferation and diﬀerentiation, and with
PPARγ found at high levels in the adipose tissues and
lower levels in colon, immune cells, and other tissues [8].
Transcriptional regulation by PPARs requires heterodimer-
ization with the retinoid X receptor (RXR), and interactions
with coregulator complexes [9–11]. When activated by a
ligand, the PPAR:RXR dimer controls transcription via
binding to the peroxisome proliferator response element
(PPRE) in the regulatory region of target genes [9]. The
selective action of PPARs in diﬀerent tissues results from
the combination, at a given time point, between expres-
sion levels of each of the three PPAR and RXR isotypes,
aﬃnity for a specific regulatory PPRE, ligand production
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by lipid-modifying enzymes, and cofactor availabilities
[12].
2. PRODUCTION OF ENDOGENOUS PPAR LIGANDS
The prevalent point of view today is that the three PPAR
isotypes function, in a broad sense, as lipid sensors that
translate lipid signals from diﬀerent origins into responses
whose aim is to maintain energy homeostasis, in response
to the diﬀerent physiologic challenges to which the body is
exposed. However, the connection between lipid metabolism
pathways and PPAR responses was only recently unveiled.
The production and nature of the endogenous ligands or
mediators of PPAR activation have not been well charac-
terized although it is known that many lipid-modifying
enzymes are involved. The pathways that generate these lipid
signals from fatty acids, which also serve as PPAR ligands, are
recapitulated in Figure 1.
ω-3 and ω-6 polyunsaturated fatty acids are stored
in membrane phospholipids and lipid bodies, and are
released by cytosolic phospholipase A2 (cPLA2) [13]. ω-
6 fatty acids, predominantly arachidonic acids, are abun-
dant in the western diet and they are often converted to
leukotrienes, prostaglandins, and other cyclooxygenase or
lipoxygenase products [13]. They regulate cellular functions
with inflammatory, atherogenic, and prothrombotic eﬀects
[13]. The ω-3 fatty acids, such as docosahexaenoic acid and
eicosapentaenoic acid, are also substrates for cyclooxyge-
nases and lipoxygenases. Interestingly, ω-3 fatty acid-derived
eicosanoids antagonize the proinflammatory eﬀects of ω-
6 fatty acids by downregulating inflammatory and lipid
synthesis genes, and by stimulating fatty acid degradation
[13]. Many eicosanoids bind to PPARs and control tissue
homeostasis and inflammation [3, 14].
The epoxygenases are a group of microsomal cytochrome
P450s (CYP) enzymes that convert arachidonic acid to
epoxyeicosatrienoic acids (EETs), which function primarily
as autocrine and paracrine mediators in the cardiovascular
and renal systems [15]. These mediators, which are unstable
and are rapidly metabolized in most tissues, have important
roles in cellular migration and proliferation, and in inflam-
mation. Although their mechanism(s) of action is not fully
understood, the epoxygenase pathway can generate potent
ligands for the PPARs, which participate in antiatherogenic,
antithrombotic, and cardioprotective processes that may be
targeted by new therapeutic developments in vascular and
inflammatory disorders [16].
The various lipases have unique pattern of expression,
distinct biological actions, and preferred substrate from
which they release diverse products [17]. They preferen-
tially hydrolyze triglycerides versus phospholipids, and use
lipoproteins, such as very low-density lipoproteins (VLDLs),
low-density lipoproteins (LDLs), and high-density lipopro-
teins (HDLs), as substrates [17]. Hydrolysis of triglycerides
within triglyceride-rich lipoproteins by the lipoprotein lipase
(LPL) results in the transfer of lipids and apolipoproteins
to HDLs. In turn, hepatic lipase (HL) hydrolyzes HDL
triglyceride and phospholipids, generating smaller lipid-
depleted HDL particles. Finally, endothelial lipase (EL)
might hydrolyze HDL phospholipids, thus promoting HDL
catabolism [17]. Lipases generate various lipolytic prod-
ucts such as fatty acids with diﬀerent chain lengths and
degrees of saturation, as well as other molecules such as
monoacylglycerol. While fatty acids can be oxidized in
order to gain energy, or alternatively stored in fat, they
can also direct transcriptional responses. PPAR activation,
as a consequence of lipolysis, underscores a key role of the
functional interplay between lipases and lipoproteins. It was
reported that LPL acts on circulating lipoproteins to generate
PPARα ligands that induce endothelial vascular cell adhesion
molecule 1 (VCAM1) [18]. LPL can release HODEs, which
are known as PPARα agonists, from electronegative LDL,
thereby reversing the proinflammatory responses of this
lipoprotein. Similarly, HDL hydrolysis, and to a lesser extent
hydrolysis of LDL and VLDL, by EL can also activate
PPARα [19, 20]. In macrophages, VLDL regulates gene
expression through activation of PPARβ/δ, an activation that
depends on the release of the VLDL triglycerides by LPL
[21]. An additional lipase, named as adipose triglyceride
lipase, desnutrin, iPLA2ζ , or transport secretion protein 2,
was identified more recently. It increases the availability
of fatty acids from VLDL, resulting in increased PPARβ/δ
activity [22–24]. Obviously, the combination of a variety of
lipases and lipoproteins and the resulting distribution in the
organism of fatty acids and their often short-lived derivatives
did not enable a precise characterization of their impact
on PPAR functions as a whole. Furthermore, activation of
PPARs by ligands produced by the diﬀerent lipid signaling
enzymes can lead to a feedback stimulation or inhibition of
the expression of these enzymes (see Section 3).
3. GUIDING LIGANDS TO PPARs: ROLES OF FABPs
Both fatty acid binding proteins (FABPs) and retinoic acid
binding proteins (CRABPs) belong to an evolutionarily
conserved family of intracellular proteins [25]. Various
functions have been attributed to these proteins, including
cellular uptake and transport of fatty acids, the targeting of
fatty acids to specific metabolic pathways, and the regulation
of gene expression and cell growth [26]. Interestingly, FABPs
are thought to deliver ligands to the PPARs. For instance,
specific interactions with fatty acid-loaded adipocyte FABP
(FABP4) and keratinocyte FABP (FABP5) selectively enhance
the activity of PPARγ and PPARβ/δ, respectively [27]. In
this function, FABPs relocate to the nucleus when bound to
ligands that are selective for the PPAR isotype they activate,
and thus FABPs mediate the transcriptional activities of
their own ligands. Retinoic acid receptors (RARs) belong to
the same type-2 class of receptors as PPARs in the nuclear
receptor superfamily [12]. A coevolution between the fatty
acid and retinoid-binding protein families and the RAR and
PPAR families can be postulated, which has promoted the
emergence of a mechanism for directing a ligand to the
appropriate receptor. The two associated systems, FABPs-
PPARs and CRABPs-RAR, show some promiscuity at the
expense of specificity, but in favor of an increased diversity in
transcriptional responses. Depending on the ratio of FABP5
to CRABP-II, RA activates RAR or PPARβ/δ. Surprisingly,
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Figure 1: PPARs are mediators of lipid signaling in inflammation and cancer. Lipid mediators originate from and participate in the
control of physiological and pathophysiological situations. Many lipid-modifying enzymes are involved in the production of PPAR ligands.
The cyclooxygenases (COX), lipoxygenases (LO), epoxygenases/cytochrome (CYP)/P450s enzymes, and the lipases use either fatty acids,
triglycerides, or phospholipids as substrates to generate PPAR ligands, which are guided to their receptors by the cytoplasmic fatty acid
binding proteins (FABPs). PPARs translate these lipid signals into responses, which maintain energy homeostasis, regulate inflammation
and modify tumor growth. Among the pathways involved in inflammation and cancer, PPARs interact with COX2, NF-κB, MAPKs, and
PTEN. PPARα and γ inhibit COX2 expression, thereby reducing the production of their own ligands. Conversely, PPARβ/δ is thought to
activate COX2 expression, generating a positive feedback loop by increasing the production of PPAR ligands. PPARs reduce inflammation
by inhibiting NF-κB, a major pathway that links chronic inflammation to cancer promotion. Several modes of interactions between PPARs
and MAPKs have been reported, but the relevance and consequences of such crosstalks are unclear. Finally, PPARβ/δ and γ decrease and
increase the expression of the tumor suppressor PTEN (phosphatase and tensin homologue deleted from chromosome 10), respectively.
PPARγ activation of PTEN is thought to potentiate its tumor suppressor function, whereas PPARβ/δ would have the opposite eﬀect.
when the FABP5-to-CRABP-II ratio is high, RA serves as
a physiological ligand for PPARβ/δ, which broadens the
spectrum of physiological regulation due to the activity of
this receptor in an unexpected way [28, 29]. The key issue
raised by these studies concerns the importance of the role
of directed ligand transport in nuclear receptor activation,
and ligand-dependent crosstalk between diﬀerent receptor
types [29]. Overruling ligand selectivity between receptor
categories by this mechanism might promote a promis-
cuity that may contribute significantly to the pleiotropic
eﬀects of key members of the nuclear receptor superfamily
[28, 29].
Similarly to the genes encoding lipid-signaling enzymes,
the expression of FABPs is controlled by PPARs in specific
situations. L-FABP is highly expressed in the liver and small
intestine, where it plays an essential role in controlling
cellular fatty acid flux. Its expression is increased by both
the fibrate hypolipidemic drugs and LCFAs. The diﬀerent
PPAR isotypes (α, β/δ, and γ) promote the upregulation
by FAs of the gene encoding L-FABP in vitro, while PPARα
is an important regulator of L-FABP in the liver, but not
in the intestine [30, 31]. In contrast, only PPARβ/δ is able
to upregulate the gene encoding L-FABP in the intestine of
PPARα-null mice. Thus, PPARβ/δ contributes to metabolic
adaptation of the small intestine to changes in the lipid
content of the diet [30, 31]. In summary, FABPs bind PPAR
ligands within the cytoplasm, channel this cargo to the
respective nuclear receptors, and by so doing influence their
activation, which sometimes regulates their own expression
[32].
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4. PPARs IN INFLAMMATION AND CANCER
Although acute inflammation is a necessary process aimed at
protecting the organism after an injury or an infection, unre-
solved chronic inflammation may promote cancer formation
by providing an appropriate environment for tumor growth
[33, 34]. Mechanisms that link inflammation and cancer
have only recently been studied, but epidemiological studies
show a convincing association between them (see [33–
36] and references therein). For example, hepatitis is often
followed by the development of hepatocarcinoma, ulcerative
colitis is a risk factor for colon cancer, and inflammation due
to infection by Helicobacter pylori precedes the majority of
gastric cancers [34]. In the lungs also, the risk of developing
lung cancer is higher in patients suﬀering from asthma or
from chronic bronchitis [37, 38].
The role of immune cells in tumor development is
not yet fully understood. Although inflammatory mediators
may promote cancer development, immune cells can also
secrete cytokines that can limit tumor progression [33–
35]. Data collected from mouse models suggest that the
role of the immune system in cancer is likely to depend
on the profile of cytokines secreted by the immune cells.
Modifying this profile may contribute to the development of
new treatments [33]. Based on present knowledge, the NF-
κB and COX2 pathways have emerged as important links
between inflammation and cancer (reviewed in [36, 39–
42]). Consistent with inflammation and COX2 favoring the
development of tumors, long-term use of NSAIDs, albeit at
relatively high doses, prevents colorectal tumor development
[43].
The roles of PPARs in tumor development are still
unclear and their pro- or anticarcinogenic eﬀects remain
open to discussion (reviewed in [7, 44]). PPAR activity has
been associated with numerous cancer types in organs such
as the liver, colon, skin, prostate, breast, and lung (reviewed
in [7, 45]). The mechanisms reported so far suggest that the
anticarcinogenic activity of PPARs is due to direct eﬀects
in the cancer cells themselves, such as inhibition of the cell
cycle, activation of cell diﬀerentiation, or cell death (reviewed
in [7, 45]). But in addition to these functions, one can
speculate that PPARs may have non-cell autonomous eﬀects
by acting on the tumor environment. In fact, PPARs regulate
inflammatory processes [3, 46, 47], and they fulfill vital
regulatory functions in cells that are important components
of the tumor stroma, such as immune or endothelial cells
[35, 48–51]. In line with the link between inflammation and
cancer promotion, we provide below an overview of PPARs’
involvement in organs in which inflammatory pathways and
cancer development are known to have been connected,
namely, the skin and the digestive tract.
4.1. Skin, inflammation, and cancer
An analysis of various models of PPAR activation or inval-
idation shows that PPARs are not absolutely indispensable
for normal epidermal maturation and renewal, but that they
accelerate mouse and human keratinocyte diﬀerentiation, as
well as mouse epidermal barrier recovery after disruption
(reviewed in [52, 53]). In addition, PPARα and PPARβ/δ
activation regulates human hair follicle survival and mouse
hair follicle growth, respectively, whereas the roles of PPARs
in the sebaceous glands remain unclear (reviewed in [52]).
After an injury, skin repair involves the recruitment
of inflammatory cells, the migration and proliferation of
keratinocytes, activation of dermal fibroblasts, and angio-
genesis [54]. Though undetectable in the interfollicular
epidermis of healthy rodent skin, the expression of PPARα
and PPARβ/δ is reactivated in the epidermis at the edges of
skin wounds [55]. The expression of PPARα is upregulated
early after the injury, but the signal involved is unknown.
The study of genetically modified mice showed that no,
or low, PPARα activity results in impaired inflammatory
reaction, which causes a transient delay in healing [55,
56]. The upregulation of PPARβ/δ expression, as well as
the production of an unknown endogenous agonist, is
triggered by proinflammatory cytokines, such as TNF-α [57],
whereas TGFβ-1 signaling is responsible for the repression
of inflammatory-induced PPARβ/δ expression at the end of
the healing process [58]. The completion of skin healing
in the PPARβ/δ-null animals is delayed, mostly because of
impaired epithelialization due to apoptosis and defects in
keratinocyte adhesion and migration [55, 59, 60]. Consistent
with decreased healing eﬃciency in its absence, prolonged
expression of PPARβ/δ accelerated wound closure [61, 62],
whereas premature downregulation of PPARβ/δ expression
temporarily delayed wound closure [62]. In summary,
PPARα and PPARβ/δ both promote the healing of skin
wounds. PPARα prevents exacerbated early inflammation,
while PPARβ/δ, whose expression and activity are increased
by inflammatory cytokines, enhances keratinocyte survival
and migration.
Inflammatory skin disorders are usually characterized by
keratinocyte hyperproliferation and aberrant diﬀerentiation,
as observed in psoriasis [63, 64]. Moreover, numerous
lipid molecules, which are potent activators of PPARs, are
produced in the psoriatic lesions where they accumulate
[65]. Consistent with stimulated expression by inflammatory
cytokines after skin injury in the mouse [57], the PPARβ/δ
levels are particularly high in the hyperproliferative lesional
skin of psoriatic patients [66], while those of PPARα and
PPARγ remain unchanged, or even decrease [65, 66]. Overall,
PPAR activation reduces inflammation in skin disorders
[53]. It is well documented that PPARα activation is
beneficial in mouse models of hyperproliferative epidermis
[67], in models of irritant and allergic dermatitis [68],
and in a model of atopic dermatitis [69]. Interestingly,
PPARα may be the molecular target of the antiallergic
and anti-inflammatory eﬀects of palmitoylethanolamide,
a natural fatty acid derivative present in murine skin
[70]. PPARγ activation also has beneficial consequences in
various models of psoriatic skin, such as in organ cultures,
in a model of human psoriatic skin transplant, and in
murine models of keratinocyte hyperproliferation [71, 72].
Despite these promising studies in models of psoriatic skin,
PPARα, PPARβ/δ, or PPARγ activation did not improve skin
homeostasis when locally applied on psoriatic plaques [73,
74]. However, PPARγ agonists thiazolidinediones eﬃciently
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normalized skin homeostasis when orally administrated to
patients suﬀering from psoriasis (reviewed in [75, 76]),
suggesting that their beneficial eﬀects are most likely due to
systemic anti-inflammatory functions of PPARγ.
The skin is constantly exposed to many types of aggres-
sion, including carcinogens such as xenobiotics or UV.
Much remains to be explored regarding PPAR functions
in skin cancers, either squamous or basal cell carcinomas
(tumors of keratinocyte origin) or melanomas (tumors
of melanocyte origin) (reviewed in [52]). Activation of
PPARα and PPARγ reduces proliferation and stimulates
diﬀerentiation of cultured melanocytes [77, 78]. Several
PPARγ agonists inhibit the proliferation of human malig-
nant melanomas [79], and the PPARα agonist fenofibrate
has antimetastatic eﬀects on melanoma tumors in vivo
in a hamster model [80]. Interestingly, combined treat-
ment with the PPARγ agonist pioglitazone, the COX2
inhibitor rofecoxib, and angiostatic chemotherapy stabilized
or even reversed chemorefractory melanoma progression,
though in only 11% of the treated patients [81]. In a
search for genetic factors that may increase melanoma
risk, correlation between PPARγ variants and melanoma
development in a Caucasian population indicated that
PPARγ polymorphisms are an unlikely risk factor for
melanoma development in this population [82]. In tumors
of keratinocyte origin, increased expression of PPARβ/δ
was reported in head and neck squamous carcinoma [83].
In a mouse model of DMBA/TPA-induced skin tumors,
PPARβ/δ-null animals showed enhanced tumor formation,
suggesting that PPARβ/δ attenuates tumor development. A
possible mechanism of this eﬀect is that, by activating the
expression of ubiquitin C, PPARβ/δ activates the ubiquitin
degradation pathway that is critical for the breakdown
of many proteins involved in cell cycle progression [84].
Another proposed mechanism is the downregulation by
PPARβ/δ of protein kinase Cα (PKCα) activity, thereby
also inhibiting keratinocyte proliferation [85]. However, the
selective ablation of PPARβ/δ in keratinocytes did not have
any incidence on the development of DMBA/TPA-induced
skin tumors, suggesting that PPARβ/δ may exert its tumor
modifier activity by acting on the tumor environment [49,
86]. It is worth noting that PPARα activators prevented
DMBA/TPA-induced skin tumors when locally applied to
mouse skin [87], and reduced UV-induced inflammation in
human skin, which is a risk factor for further development
of UV-induced skin cancers [88]. On the contrary, the
activation of PPARγ did not prevent the development
of UV- or DMBA/TPA-induced skin tumors [89], despite
increased susceptibility of PPARγ+/− and keratinocyte-
selective PPARγ-null mice to DMBA-mediated carcinogen-
esis [86, 90]. Finally, UV treatment of a human keratinocyte
cell line induced the production of an unknown PPARγ
activator [91], but the relevance of this observation remains
unclear.
Taken together, these many observations underscore
the implications of PPARs in inflammatory skin disorders,
UV-induced inflammation, and tumor development. So
far, PPARγ activation in patients has proven eﬃcient to
treat psoriasis, but other therapeutical applications remain
to be explored and defined, particularly in the field of
carcinogenesis.
4.2. Digestive tract inflammation
Inflammatory bowel diseases (IBDs) are inflammatory dis-
eases aﬀecting the small or the large intestine [92]. Crohn’s
disease and ulcerative colitis are the best known forms
of IBDs although their causes remain unclear. In their
acute phase, IBDs are characterized by acute inflammation,
involving the recruitment of immune cells and an elevated
production of cytokines. Under chronic conditions, abnor-
mal intestinal epithelium morphology and scarring develop.
In various animal models of IBD, the activation of PPARα
or PPARγ has anti-inflammatory eﬀects in the intestine,
resulting in decreased production of inflammatory markers
and slower progression of colitis [93–96]. In these models,
PPARγ is the best studied isotype. With the exception of one
contradictory study showing that long-term pretreatment
with a PPARγ agonist aggravated colitis [97], the preventive
activation of PPARγ was eﬃcient, whereas the eﬃcacy of lig-
and administration after the onset of the disease was depen-
dent on the levels of PPARγ [95, 98–100]. PPARγ activation
also prevented colon damage caused by immobilization-
induced stress [101]. Conversely, enhanced susceptibility to
colitis was observed in mice with reduced PPARγ levels or
activity [95, 102–105]. The bases of the protective action
of PPARγ in colitis are reduced proinflammatory cytokine
production, attenuated expression of ICAM-1 and COX-2,
inhibition of NF-κB and JNK/p38 MAPK, and modification
of immune cell activity [44, 95, 98, 99, 102, 105–107]. In
patients suﬀering from active ulcerative colitis, a twelve-week
treatment with the PPARγ agonist rosiglitazone eﬃciently
cured four out of fifteen patients [108]. Furthermore PPARγ
is thought to be one of the molecular targets underlying
the beneficial anti-inflammatory eﬀect of 5-aminosalicylic
acid, a drug widely used to treat inflammatory bowel diseases
(IBDs) [109]. Together, these treatments confirm PPARγ as
a potential target in IBDs. The beneficial role of PPARγ
activation in inflammatory diseases of the digestive tract
may not be limited to the intestine, but seems to extend
to gastritis and pancreatitis, an inflammation of the gastric
mucosa and pancreas, respectively. In several models of
gastritis or gastric ulcers, activation of PPARγ attenuates
mucosa damage and accelerates healing, via reduction of
inflammation, apoptosis, and lipid peroxidation [110–115].
As in the stomach, PPARγ activity is beneficial in vari-
ous animal models of pancreatitis, reducing inflammation,
restoring exocrine pancreas functions, and limiting chronic
pancreatitis development [116–121].
In addition to its already mentioned anti-inflammatory
eﬀects, PPARα protects the intestine from colitis-induced
permeability [122]. So far, the benefits of PPARβ/δ activation
in colitis are poorly documented [44]. One report suggested
that PPARβ/δ-null mice exhibit more severe damage in a
model of DSS-induced colitis, whereas a PPARβ/δ agonist
had no protective or deleterious eﬀect when administrated
to PPARβ/δ-wt or -null animals [123]. This observation
suggests not only that PPARβ/δ protects wt animals against
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DSS-colitis, but also that this protective eﬀect may be ligand-
independent or triggered by a so far nonidentified ligand.
The liver is an additional target organ of PPARs for
the control of inflammation. Prolonged liver inflammation,
which is deleterious, usually activates hepatic stellate cells
(HSCs), also known as Ito cells or lipocytes, which pro-
liferate, transdiﬀerentiate into myofibroblasts, and produce
excess extracellular matrix, finally leading to severe fibrosis
and end-stage cirrhosis [124]. Animal models suggest that
limiting, or even reversing, fibrosis may be possible by
reducing inflammation, enhancing HSC apoptosis, blocking
HSC transdiﬀerentiation, or stimulating ECM degradation
[124]. Although PPARβ/δ activation seems to enhance
fibrosis via activation of HSC [125], increasing PPARα
or PPARγ activity appears to have antifibrotic eﬀects.
PPARα reduces inflammation and oxidative stress [126,
127], and PPARγ decreases HSC proliferation, reverses their
profibrotic activity, and counteracts the TGFβ1-induced
production of collagen [128–136]. Recently, PPARγ activity
in human hepatic stellate cells has been shown to be inhibited
by acetaldehyde, the major product of ethanol oxidation and
one of the main mediators of alcohol-induced liver fibrosis
[137].
In conclusion, manipulating the balance of PPAR isotype
activities is an interesting therapeutic concept when used to
control inflammation of the digestive tract and associated
glands.
4.3. Digestive tract and cancer
As the literature includes extensive recent reviews on the
interaction between PPARs and Wnt/Apc, known to play
a major role in colorectal cancer progression [7, 138], this
paragraph will focus on data dealing with chronic inflamma-
tion as a risk factor for colon carcinogenesis. Inflammatory
bowel diseases, particularly ulcerative colitis, increase the
risk of colorectal cancer in patients [139]. As discussed
above, PPARγ activation has protective eﬀects in animal
models of ulcerative colitis (reviewed in [140]). Moreover,
activation of PPARα and PPARγ in rodents reduced the
formation of aberrant crypt foci, a risk factor for colon
cancer [94]. However, the PPARγ agonists pioglitazone and
rosiglitazone had no eﬀect on the development of tumors
in a mouse model of azoxymethane/dextran sodium sulfate-
induced colon cancer, whereas in the same study the anti-
inflammatory 5-ASA reduced the number and the size of
the tumors [141], showing that PPARγ is certainly not
the only target of 5-ASA. However, in a diﬀerent study,
COX2 inhibitors, the PPARγ agonist troglitazone and, to
a lesser extent, the PPARα agonist bezafibrate, reduced
the development of adenocarcinoma in a mouse model of
azoxymethane/dextran sodium sulfate-induced colon cancer
[142, 143].
Chronic inflammation finally leading to cancer may also
arise from infections, as in the stomach where infection
by Helicobacter pylori is a common risk factor for gastric
cancer [144]. PPARγ expression is increased in gastric
epithelia infected by Helicobacter pylori. The consequences
of upregulated PPARγ expression are unknown, but it may
contribute to reducing inflammation [145]. The treatment
of gastric cancer patients with the COX2 inhibitor rofecoxib
correlated with increased levels of PPARγ in the tumor [146].
An epidemiological study performed in a restricted region of
Japan suggested that the Pro12Ala variant of PPARγ, which
is less active than the wt protein, might be associated with
increased risk of gastric cancer [147].
Pancreatic cancer is still lethal in most cases, due to the
lack of early markers and specific symptoms and because of
aggressive tumor growth and resistance to treatments [148].
While PPARγ activation shows beneficial anti-inflammatory
eﬀects in the pancreas, the consequences of such activation
in patients with pancreatic cancer are unknown. In vitro
data show that PPARγ inhibits pancreatic cell proliferation,
which would be beneficial, but also suggest that PPARγ may
activate angiogenesis through induced VEGF expression,
which would be detrimental (reviewed in [148]). In one
in vivo study, however, the PPARγ agonist pioglitazone
prevented cancer in a hamster model [149]. In human
patients, a high level of PPARγ expression correlated with
high-grade pancreatic carcinoma [150]. The mechanism
responsible for this eﬀect remains unknown.
4.4. Age-related diseases
Oxidative stress and inflammation increase with age, and
further enhancement by environmental factors is thought to
favor the development of age-related diseases and cancers.
Although this is not fully clear in human, slight caloric
restriction diet may retard these processes. The roles of
PPARs in age-related inflammation and associated diseases
have been reviewed recently in [151–153]. In short, PPARs
are thought to be involved in age-related inflammation,
caloric restriction physiology, and longevity. Increased
inflammation levels during aging are correlated to decreased
PPAR activity. Conversely, administration of the PPARα
activator Wy14,643 improved the redox balance and reduced
inflammation in aged mice [154, 155]. A similar inhibition
of age-related inflammation was observed in rat kidney after
feeding with a PPARγ agonist [156]. Interestingly, among
flavonoids found in fruits and vegetables, which have been
associated with decreased risk of inflammation-mediated
diseases, some are PPARγ agonists that are known to decrease
proinflammatory mediator production. For instance, cur-
cumin, a naturally occurring compound in turmeric, has
been used in India for centuries as an anti-inflammatory
agent. It is thought to be a PPARγ activator and was suggested
to have beneficial eﬀect on colorectal cancer when taken on a
daily basis [152, 157].
5. CROSSTALK BETWEEN PPARs AND PATHWAYS
RELEVANT TO CANCER AND INFLAMMATION
It is obvious from the above that PPARs interact with numer-
ous pathways involved in cancer development (reviewed in
[7, 45, 158]). For instance, PPARα regulates the expression of
miRNA let-7C in hepatocytes, a tumor suppressor gene that
regulates cancer cell proliferation. PPARβ/δ is a downstream
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target of two pathways often involved in colon cancer devel-
opment, namely, the Ras and the APC-β-catenin pathways.
PPARβ/δ also controls the PTEN/Pi3K/Akt pathway, whose
actors are often associated with cancer, and promotes cell
migration via activation of the Rho-GTPases [60]. Finally,
PPARγ activation can induce growth arrest, diﬀerentiation,
or apoptosis in many cancer cells [7].
In the next sections, we summarize the interaction
of PPARs with the main pathways involved in the con-
trol of inflammatory responses and cancer development
[3, 46].
5.1. COX2 as a link to lipid mediators
Cyclooxygenases (COX) are the enzymes that catalyze the
first steps of the production of prostaglandins from arachi-
donic acid. The COX1 isoform is constitutively expressed
in most tissues, whereas the expression of COX2 is induced
in inflamed tissues and in tumors. Genetic, epidemiological,
and pharmacological evidence supports the hypothesis that
elevated COX2 activity is involved in tumor progression
(reviewed in [159–161]). Laboratory experiments as well
as clinical studies have shown that COX2 inhibitors are
promising antitumoral compounds to combine with other
anticancer treatments. However, there is a need to develop
new compounds with reduced risk of cardiovascular side
eﬀects (reviewed in [40, 159, 161, 162]). Antitumoral
activity of COX2 inhibitors most probably results from a
combination of eﬀects on angiogenesis, apoptosis, tumor
cell invasiveness, and inflammation. Interestingly, PPARα
and γ activation may help in inhibiting the activity of
COX2 by reducing its expression. PPARα agonists prevented
PMA-induced expression of COX2 and VEGF [163], and
the PPARγ agonist ciglitazone decreased the expression of
COX2 and cJun in a colorectal cancer cell line [164]. COX2
can also modify PPAR activity since some of the COX-2-
produced fatty acid derivatives are PPAR activators. COX2
has been proposed to modify the activity of PPARβ/δ in
colorectal cancer by producing activators such as PGI2 [165–
167] or PGE2, which indirectly increase PPARβ/δ activity
[168]. In human cholangiocarcinoma cell lines, activation
of PPARβ/δ was shown to increase cell proliferation by
increasing the expression of COX2 and thus the production
of PGE2 [169]. In this model, PGE2 is meant to subsequently
activate PPARβ/δ indirectly via cPLA2α, thereby triggering a
positive feedback loop controlling cholangiocarcinoma cell
proliferation. Inhibiting COX2 is likely to result in decreased
PPAR activity. This was in fact demonstrated in hair follicle
growth of murine skin, during which inhibition of COX2
replicates the phenotype of PPARβ/δ-null animals [170].
However, increased PPARγ activity by COX2 inhibitors was
also reported, although the mechanism remains unknown
(reviewed in [148]). The COX2 and PPAR pathways are
certainly interconnected, but to what extent the PPAR
activity contributes to the COX2 cancer promotion function
is unclear. However, drug-combined modification of PPAR
activity in inflammation and cancer is an interesting thera-
peutic prospect.
5.2. NF-κB links inflammation to cancer
The NF-κB pathway is an important link between inflam-
mation and cancer (see [41]; reviewed in [36, 42]). The
three PPARs are able to antagonize this pathway, via their
transactivation or transrepression activities, thereby leading
to the repression of several genes involved in inflammation
[3, 44, 47]. In colon cancer cell lines, the PPARγ agonist
15d-PGJ2 attenuated the production of IL-1β-induced IL-
8 and MCP-1 by inhibition of NF-κB activity [96], and
induced apoptosis via NF-κB and Bcl-2 [171]. In the liver, the
disruption of NF-κB signaling resulted in the suppression of
PPARα-increased expression during a high-fat diet, whereas,
in parallel, an increase in PPARγ expression was observed.
In these mice, liver steatosis (a consequence of decreased
FA oxidation and increased expression of genes involved
in lipogenesis), inflammation, and development of liver
cancer were aggravated [172]. Animal and preclinical studies
showed that an ω-3 fatty acid supplement to the diet should
provide a useful complement to cancer therapy, slowing
down progression of various tumors and improving patients’
quality of life [173]. Among the mechanisms proposed
for these beneficial eﬀects, ω-3 fatty acids repress the NF-
κB function and Bcl-2 expression, which in turn leads to
decreased COX2 expression and restoration of functional
apoptosis [173]. In addition to PPARs regulating the activity
of NF-κB, the p65 subunit of the latter was shown to
inhibit the transcriptional activity of PPARγ on adipocyte
gene expression [174] and of the three PPARs in transfected
keratinocytes [65], suggesting that a reciprocal regulation
between the two pathways exists.
5.3. MAPK pathway as a major player in
carcinogenesis
The MAPK pathway is activated by cytokines, and its
overactivation is found in the vast majority of cancer
cells and tumors (reviewed in [175]). Phosphorylation of
PPARα and PPARγ by this pathway increases or decreases
their transcriptional activity, respectively (reviewed in [9,
176]). The physiological impact of the regulation of PPAR
activity through phosphorylation has mostly been addressed
for PPARα and γ regarding insulin signaling and fatty
acid metabolism, but the impact of this modification on
inflammation or cancer is currently not documented [9,
176]. Nevertheless, PPAR and MAPK crosstalk has been
described in immune or cancer cells. In its unliganded
form, PPARα suppressed p38 MAPK phosphorylation in
CD4(+) T cells. Ligand activation reversed this inhibition,
resulting in the expression of the transcription factor of
T cells (T-bet), a marker of Th1 inflammatory responses
[177]. The PPARγ agonist rosiglitazone attenuated TNBS-
induced colitis via inhibition of the activity of the MAPKs
p38 and the c-Jun N-terminal kinase (JNK), and of NF-κB,
thereby limiting the expression of proinflammatory genes
[95]. In a human colon cancer cell line, PPARγ activation
was reported to increase the expression of caveolin1, a
protein that is linked to cancer development [178]. This
induction seemed to result from an activation of the MAPK
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pathway by PPARγ. In another study, the activation of
PPARγ in turn activated the Rho-GTPase/MEK1/ERK1/2
cascade, resulting in morphological changes and increased
motility in rat intestinal epithelial cells [179]. In lung
cancer cell lines, the PPARγ agonist troglitazone induced
cell diﬀerentiation, probably via activation of Erk1/2 [180,
181]. In addition, the Erk5-dependent activation of PPARγ
seemed to be responsible for the antitumorigenic eﬀect of
the Wnt signaling pathway [182]. PPARβ/δ also interacts
with the MAPK pathway. When activated by TNFα, the
MAPK pathway induced the expression of the PPARβ/δ
gene in inflamed keratinocytes [57]. Once activated by a
ligand produced in parallel, PPARβ/δ facilitates keratinocyte
survival and migration. Interestingly, both the expression
of PPARβ/δ and the activity of the MAPK pathway are
elevated in many tumors [7, 175]. Whether the expression
of PPARβ/δ is stimulated by this pathway in cancers remains
to be investigated. Finally, anti-inflammatory eﬀects of
the MEK5/Erk5 pathway in a muscle cell line are due to
inhibition of NF-κB and are thought to involve PPARβ/δ
activation [183].
Crosstalk between PPARs and MEKs, the upstream
regulators of the MAPK, has also been described [184].
It has been suggested that MEK1 interacts with PPARγ,
thereby causing PPARγ delocalization from the nucleus to
the cytoplasm [185]. Interestingly, PPARγ was described
as mainly cytoplasmic in human biopsies of salivary duct
carcinoma and breast cancer [186, 187]. Although the
significance of this shuttling is unclear, it should decrease
PPARγ transactivation functions.
5.4. PTEN/Pi3K pathway and its target mTOR
The phosphatase and tensin homologue deleted from chro-
mosome 10 (PTEN) is a tumor suppressor whose activity is
lost in many human cancers. PTEN is a lipid and protein
phosphatase whose main substrate is the PIP3 produced by
the Pi3K. Through its phosphatase activity, PTEN antag-
onizes PiK3 activity and inhibits the Pi3K/Akt pathway
involved in the regulation of apoptosis, cell proliferation and
growth, and metabolism [188, 189]. The mammalian target
of rapamycin (mTOR), one of the targets of the PTEN/Pi3K
pathway, is a conserved kinase that regulates central cellular
functions in response to environmental signals, such as
transcription and translation, mRNA and protein turnover,
or autophagy (reviewed in [190, 191]). Impaired mTOR
pathway is often associated with tumorigenesis [1]. PPARβ/δ
was shown to indirectly inhibit the expression of PTEN
in keratinocytes, thereby activating the Pi3K/Akt pathway,
which enabled keratinocyte survival [59]. In lung carcinoma
cells, the activation of PPARβ/δ stimulated cell proliferation,
via decreased expression of PTEN and activation of NF-κB
and Pi3K/Akt [192, 193]. While PPARβ/δ decreases PTEN
expression, PPARγ activation has the opposite eﬀect. In a
model of allergic inflammation in mouse lung, PPARγ ago-
nists decreased inflammation, most probably via increased
PTEN expression, and reduced PiP3 levels as well as Akt
and NFκB activities [194]. Treatment of lung carcinoma cell
lines with rosiglitazone decreased proliferation via PPARγ-
dependent upregulation of PTEN and inhibition of Akt
activity, and also via PPARγ-independent inhibition of the
mTOR pathway [195, 196]. PPARγ-independent inhibition
of mTOR by TZD was also reported in keratinocytes [197].
In this model, TZD inhibited the mitogenic eﬀect of IGF
via indirect inhibition of mTOR, a mechanism which may
be involved in TZD-mediated inhibition of skin tumor
development in transgenic mice overexpressing IGF.
In a hepatocarcinoma cell line, PPARγ activation by
rosiglitazone inhibited cell migration through increased
expression of PTEN [198]. Rosiglitazone also had important
anticarcinogenic eﬀects in some highly aggressive anaplastic
thyroid cancer cell lines. In these cells, rosiglitazone induced
apoptosis, cell cycle inhibition, diﬀerentiation, and decreased
anchorage-independent growth and migration. This was at
least partially due to upregulation of PTEN and inhibition of
Akt activity, which antagonized IGF-1 eﬀects necessary for
the progression of thyroid cancers [199].
In summary, PPARβ/δ and γ are both regulators of the
expression of PTEN, and interact with the mTOR pathway.
PPARβ/δ decreases PTEN expression, whereas PPARγ acti-
vates this tumor suppressor gene.
6. CONCLUSIONS
In numerous cancer types, PPARs regulate autonomous
processes in tumor cells, such as apoptosis, proliferation,
and diﬀerentiation, by interacting with major pathways
involved in carcinogenesis. They also act on the tumor cell
environment, modifying angiogenesis, inflammation, and
immune cell functions (reviewed in [3, 7, 45, 48–51]).
Not surprisingly, their activation has complex consequences,
in which the contribution of tumor cell-autonomous ver-
sus nonautonomous mechanisms remains to be evaluated.
Whether PPARs are pro- or anticarcinogenic actors is still
open to discussion, and may depend not only on the origin
and genetics of the tumor cell, but also on the nature
of the host tissue and inflammation levels. Although the
possible carcinogenic or toxic eﬀects of PPAR activation
remain an unresolved issue, PPARs nevertheless constitute
valuable therapeutic targets (reviewed in [7, 200]). The use
of PPARα and PPARγ agonists is increasing in the treatment
of a constantly expanding number of diseases related to
the metabolic syndrome. In this context, although their
supposedly carcinogenic or toxic eﬀects have to be carefully
monitored, PPARs are important therapeutic targets. Many
valuable approaches are now under investigation in order
to better understand the mechanisms of adverse eﬀects,
and to develop better compounds. In vivo models, such as
tissue or cell-type selective PPAR knock-out mice, as well
as humanized animals carrying the human PPAR genes, will
certainly help in sorting out the various actions of PPARs in
inflammation and cancer. In addition, the development of
selective PPAR modulators (SPPARMs), rather than PPAR
full agonists, which would retain most of the benefits
while reducing the adverse eﬀects of PPAR activation, is
a promising approach. For all these reasons, PPARs are
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certainly useful pharmaceutical targets to be explored further
in the context of inflammation and/or cancer therapy.
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